Medicis Licenses Proprietary Peptide Technology From Ansata Therapeutics, Inc.
10/19/2005 5:12:28 PM
SCOTTSDALE, Ariz. and VILLAGE OF LA JOLLA, Calif.--(BUSINESS WIRE)--Dec. 14, 2004--Medicis (NYSE:MRX) and Ansata Therapeutics, Inc. ("Ansata") today announced they have entered into an exclusive development and license agreement and other ancillary agreements. The development and license agreement grants Medicis the exclusive, worldwide rights to Ansata's early-stage, proprietary antimicrobial peptide technology.
comments powered by